Abstracts tagged "Lupus nephritis"

Abstract Number: 2153 • 2018 ACR/ARHP Annual Meeting
The Effect of Socioeconomic Status on Treatment Outcomes in Lupus Nephritis: Private Versus Public Insurance
Arezoo Haghshenas¹, Phildrich Teh², Kristal Choi³, Abigail Benitez⁴, Lorena Salto³, Mathew Firek⁵, Karina Torralba⁶ and Vaneet K. Sandhu¹, ¹Division of Rheumatology, Loma Linda University, Loma Linda, CA, ²Internal Medicine, University of California, Riverside, Riverside, CA, ³Loma Linda University, Loma Linda, CA, ⁴Rheumatology, Loma Linda University, Loma Linda, CA, ⁵Riverside university health system, Moreno valley, CA, ⁶Loma Linda University Medical Center, Loma Linda, CA
Background/Purpose: Despite therapeutic advancements, lupus nephritis (LN) remains a major cause of mortality among patients with SLE. Loma Linda University Health serves a region in…
Abstract Number: 2416 • 2018 ACR/ARHP Annual Meeting
Good Pregnancy and Neonatal Outcomes in Lupus Nephritis Patients with Complete Remission
Weixin HU, Kang LI, Yinghua CHEN, Zhenzhao LIU, Liu YANG, Duqun CHEN and Haitao Zhang, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China
Background/Purpose: To investigate the outcomes of pregnancy and neonatal and the risk factors of lupus flares and pregnancy complications in Chinese patients with lupus nephritis…
Abstract Number: 2436 • 2018 ACR/ARHP Annual Meeting
The Impact of Different Classes of Lupus Nephritis on Maternal and Fetal Outcomes
Bruna Costa Rodrigues¹, Marcela Ignacchiti Lacerda¹, Guilherme Ramires de Jesus², Flavia Cunha dos Santos², Nilson Ramires de Jesus², Roger Abramino Levy^1,3 and Evandro Mendes Klumb¹, ¹Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Immunology and Inflammation, GlaxoSmithKline, Upper Providence, PA
Background/Purpose: During pregnancy, history of lupus nephritis (LN) has been independently associated with increased risk of adverse maternal and fetal outcomes, which are even more…
Abstract Number: 2636 • 2018 ACR/ARHP Annual Meeting
Investigating Lupus Nephritis Patient Outcomes Receiving Belatacept Post Renal Transplant Using the UNOS Database
Osman Bhatty¹, Sarah Aurit², Rouhin Sen³, Joseph Nahas⁴ and Sunil Jagadesh⁵, ¹Department of Medicine, CHI Creighton University Medical Center, New Hempstead, NY, ²Department of Surgery, CHI Creighton University Medical Center, Omaha, NE, ³Internal Medicine, CHI Creighton University Medical Center, Omaha, NE, ⁴Department of Rheumatology, CHI Creighton University Medical Center, Omaha, NE, ⁵Department of Nephrology, CHI Creighton University Medical Center, Omaha, NE
Background/Purpose: Twenty to sixty percent of patients with systemic lupus erythematous (SLE) can progress to lupus nephritis (LN) and those that do can develop end…
Abstract Number: 2662 • 2018 ACR/ARHP Annual Meeting
Changes in Blood Pressure and Proteinuria at One Year in Two Lupus Nephritis Clinical Trials
L. Michelle Gomez Mendez¹, Marco Prunotto², Jian Dai³, Paul Brakeman¹, Maria Dall'Era¹, Jay Garg³ and Matthew Cascino³, ¹UCSF, San Francisco, CA, ²Hoffmann-La Roche, Basel, Switzerland, ³Genentech, Inc., South San Francisco, CA
Background/Purpose: Hypertension predicts poor long-term renal outcomes for patients with lupus nephritis (LN) [1, 2]. We sought to characterize relationships between blood pressure and proteinuria…
Abstract Number: PP11 • 2018 ACR/ARHP Annual Meeting
The Road Less Traveled– Nontraditional Approaches to Increased Patient Adherence and Positive Outcomes
Carlene Harrison, AstraZeneca, Gaithersburg, MD
Background/Diagnosis: African-American female diagnosed with SLE, Lupus Nephritis, Discoid Lupus, and Raynaud’s Phenomenon in 2011. Symptoms included joint pain, edema in the ankles, malar rash,…
Abstract Number: 2851 • 2018 ACR/ARHP Annual Meeting
NF-Κappa b Signaling in the Myeloid Cell Lineage Drives the Pathogenesis of Immune-Mediated Nephritis
Samantha Chalmers¹, Sayra Garcia¹, Justine Shum¹, Leal Herlitz² and Chaim Putterman³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Cleveland Clinic, Cleveland, OH, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Immune-mediated glomerulonephritis is a serious end organ pathology that commonly affects patients with systemic lupus erythematosus (SLE). Nephrotoxic serum nephritis, induced by passive transfer…
Abstract Number: 173 • 2017 ACR/ARHP Annual Meeting
Applying Urine Proteomics for Discovery of Lupus Nephritis Damage Biomarkers in a Pediatric Cohort
Jessica Turnier¹, Bruce Aronow², Kenneth Greis³, Michael Bennett⁴, Wendy Haffey³, Sherry Thornton⁵, Gaurav Gulati⁶, Michael Wagner⁷, David Witte⁸, Prasad Devarajan⁹ and Hermine I. Brunner¹⁰, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Computational Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ⁷Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Non-invasive biomarkers of lupus nephritis (LN) damage are needed to guide treatment decisions and determine risk for kidney failure. Urinary proteomics has advanced as…
Abstract Number: 665 • 2017 ACR/ARHP Annual Meeting
Low Vitamin D Is Associated with End Stage Renal Disease in Systemic Lupus Erythematosus
Michelle Petri¹, Wei Fu² and Daniel Goldman², ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Vitamin D insufficiency/deficiency is common in SLE. Replacement therapy may help renal disease activity. We asked whether low vitamin D predicted later organ damage.…
Abstract Number: 668 • 2017 ACR/ARHP Annual Meeting
Is Uric Acid Level a Predictor of Long-Term Renal Outcome in Lupus Nephritis?
Michelle Lopes¹, Samara Gavinier², Elaine Leon², Vilma Viana², Eduardo Ferreira Borba¹ and Eloisa Bonfa³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, São Paulo, Brazil, ³Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Hyperuricemia has been reported to be associated with chronic kidney disease (CKD) in several clinical conditions, and recent studies also observed an association between…
Abstract Number: 671 • 2017 ACR/ARHP Annual Meeting
A New Histological Index for Predicting a Decline in Kidney Function in Patients with Lupus Nephritis. a Mexican Cohort Study of 186 Patients with a Kidney Biopsy
Marco Ulises Martinez-Martinez¹, Cesar Eduardo Vallín Orozco², David Martínez-Galla³ and Carlos Abud-Mendoza⁴, ¹Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, ²Rheumatology, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, ³Pathology, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, ⁴Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico
- Background/Purpose: The NIH indexes (of activity and chronicity) were proposed by Austin et al., in 1984. At the moment, there are therapies which can…
Abstract Number: 672 • 2017 ACR/ARHP Annual Meeting
Baseline Hyperuricemia As a Predictive Value for Development of Lupus Nephritis in Premenopausal SLE Patients
Doo-Ho Lim¹, Seokchan Hong², Ji Seon Oh³, Yong-Gil Kim², Chang Keun Lee², Seung Won Choi¹ and Bin Yoo², ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, National Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: Although lupus nephritis is a common and serious manifestation of SLE, there have been few predictive markers for development of lupus nephritis in SLE…
Abstract Number: 702 • 2017 ACR/ARHP Annual Meeting
Positive Direct Coombs’ Test in the Absence of Hemolytic Anemia Predicts High Disease Activity and Poor Renal Response in Systemic Lupus Erythematosus
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Direct Coombs' test in the absence of hemolytic anemia was newly included in the immunologic criterion of the SLICC/ACR 2012 criteria for SLE. Since…
Abstract Number: 1843 • 2017 ACR/ARHP Annual Meeting
Serum Albumin at 12 Months Post Biopsy Has Excellent Sensitivity and Specificity for Favorable 4 Year Renal Outcome in Lupus Nephritis (LN)
Vinicius Domingues¹, Nicole Bornkamp¹, Benjamin A. Levinson², Judith D. Goldberg², Jill P. Buyon¹ and H. Michael Belmont¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Population Health, New York University School of Medicine, New York, NY
Background/Purpose: LN is a common, deleterious manifestation of systemic lupus erythematosus (SLE) and despite recent advances in treatment remains the most significant end organ injury…
Abstract Number: 1920 • 2017 ACR/ARHP Annual Meeting
Tacrolimus Induces Remission in Refractory and Relapsing Lupus Nephritis By Decreasing P-Glycoprotein Expression and Function on Peripheral Blood Lymphocytes
Vikas Gupta, Sukesh Edavalath, Mohit Kumar Rai, Harshit Singh, Saurabh Chaturvedi and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: About 15-30% of Lupus Nephritis (LN) patients do not respond to first-line immunosuppressive therapy. P-glycoprotein (P-gp) mediated efflux of corticosteroids (CS) may contribute to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].